ArticleActa biomaterialia2015
Focal therapy of neuroblastoma using silk films to deliver kinase and chemotherapeutic agents in vivo.
Article in Acta biomaterialia, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 50 citations in OpenAlex.
- Recent developments in natural biopolymer based drug delivery systems.RSC advances · 2023Review
- Review
- Development of a dinutuximab delivery system using silk foams for GD2 targeted neuroblastoma cell death.Journal of biomedical materials research. Part A · 2021Article
- Enhancing sustained-release local therapy: Single versus dual chemotherapy for the treatment of neuroblastoma.Surgery · 2020Article
- Local delivery of dinutuximab from lyophilized silk fibroin foams for treatment of an orthotopic neuroblastoma model.Cancer medicine · 2020Article
- Silk Particle Production Based on silk/PVA Phase Separation Using a Microfabricated Co-flow Device.Molecules (Basel, Switzerland) · 2020Article
- Silk Reservoirs for Local Delivery of Cisplatin for Neuroblastoma Treatment: In Vitro and In Vivo Evaluations.Journal of pharmaceutical sciences · 2019Article
- Extended release formulations using silk proteins for controlled delivery of therapeutics.Expert opinion on drug delivery · 2019Review
- Down-regulation of MYCN protein by CX-5461 leads to neuroblastoma tumor growth suppression.Journal of pediatric surgery · 2019Article
- Sustained release silk fibroin discs: Antibody and protein delivery for HIV prevention.Journal of controlled release : official journal of the Controlled Release Society · 2019Article
- Pharmaceutical Approaches to HIV Treatment and Prevention.Advanced therapeutics · 2018Article
- Disseminated injection of vincristine-loaded silk gel improves the suppression of neuroblastoma tumor growth.Surgery · 2018Article
- Avidin Adsorption to Silk Fibroin Films as a Facile Method for Functionalization.Biomacromolecules · 2018Article
- In vitro and in vivo evaluation of etoposide - silk wafers for neuroblastoma treatment.Journal of controlled release : official journal of the Controlled Release Society · 2018Article
- Article
- Honeysuckle flowers extract loaded Bombyx mori silk fibroin films for inducing apoptosis of HeLa cells.Microscopy research and technique · 2017Article
- Manipulation of variables in local controlled release vincristine treatment in neuroblastoma.Journal of pediatric surgery · 2017Article
- Supercritical carbon dioxide-developed silk fibroin nanoplatform for smart colon cancer therapy.International journal of nanomedicine · 2017Article
- Clinical Considerations of Focal Drug Delivery in Cancer Treatment.Current drug delivery · 2017Review
- Sustained delivery of vincristine inside an orthotopic mouse sarcoma model decreases tumor growth.Journal of pediatric surgery · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 2 countries.
Funding
Abstract
Current methods for treatment of high-risk neuroblastoma patients include surgical intervention, in addition to systemic chemotherapy. However, only limited therapeutic tools are available to pediatric surgeons involved in neuroblastoma care, so the development of intraoperative treatment modalities is highly desirable. This study presents a silk film library generated for focal therapy of neuroblastoma; these films were loaded with either the chemotherapeutic agent doxorubicin or the targeted drug crizotinib. Drug release kinetics from the silk films were fine-tuned by changing the amount and physical crosslinking of silk; doxorubicin loaded films were further refined by applying a gold nanocoating. Doxorubicin-loaded, physically crosslinked silk films showed the best in vitro activity and superior in vivo activity in orthotopic neuroblastoma studies when compared to the doxorubicin-equivalent dose administered intravenously. Silk films were also suitable for delivery of the targeted drug crizotinib, as crizotinib-loaded silk films showed an extended release profile and an improved response both in vitro and in vivo when compared to freely diffusible crizotinib. These findings, when combined with prior in vivo data on silk, support a viable future for silk-based anticancer drug delivery systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.